Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?

International Journal of Immunotherapy and Cancer Research

Case Report

Are Cladribine and Rituximab Enough for the Treatment of

Relapsed Hairy Cell Leukemia?

Abstract
Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons.

http://www.peertechz.com/Immunotherapy-Cancer-Research/pdf/IJICR-1-102.pdf

Comments

Popular posts from this blog

Successful treatment of Budd- Chiari Syndrome with Percutaneous transluminal Balloon Angioplasty

Case Report: Reynolds Syndrome

Ministernotomy Thymectomy in Mysthania Gravis-Future